Enveda ENV-308 Lac-Phe-Mimetic Pill Phase 1 Muscle Preservation Data Continues to Drive Post-GLP-1 Discontinuation Discussion
Enveda Biosciences (Boulder, Colorado; AI-enabled natural product discovery platform) continues to draw attention through September 2026 for ENV-308, the first-in-class oral small-molecule mimetic of Lac-Phe (N-lactoyl-phenylalanine, an exercise-produced signaling molecule) whose Phase 1 safety and tolerability data was reported August 18, 2026. The Phase 1 trial in 88 healthy volunteers showed ENV-308 was well-tolerated with low GI side effects and reduced circulating leptin as a biomarker signal that the drug reaches metabolically-active concentrations in humans. In preclinical animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that roughly 1 in 8 U.S. adults have used a GLP-1 medication and most stop within a year for cost, side-effect, or plateau reasons. Phase 2 will test whether ENV-308 helps people maintain weight after stopping GLP-1s. Timeline: realistic earliest approval 2028-2029. ENV-308 joins bimagrumab (Eli Lilly, anti-activin receptor Phase 3), HM17321 (Hanmi-Genentech UCN2 analog, Phase 1), and ARO-INHBE (Arrowhead RNAi, Phase 1/2a) in the muscle-preservation pipeline.